Search

The article offers information regarding the Genetic Information Nondiscrimination Act (GINA). GINA mandates nondiscriminatory acts among people with genetically modified disease that restricts them from getting a job and insurances. Yet, it does not regard provisions for life insurance industry. It analyzes the effect of GINA on state laws, particularly the genetic discrimination law in New Jersey. It considers the rectification of GINA to assert anti-discrimination in life insurance companies.

The article focuses on interest in rare diseases by pharmaceutical companies. It talks about the pharmaceutical company Shire which in 2005 lost patent protection for its attention-deficit drug Adderall XR; Shire responded by acquiring Transkaryotic Therapies that held a handful of drugs for rare genetic diseases. It comments on orphan drug laws in Europe and the U.S. that offer tax breaks and market exclusivity that has increased interest by larger pharmaceuticals in rare disease drugs.